Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy

被引:15
作者
Helbekkmo, Nina [1 ,2 ]
Aasebo, Ulf [2 ,3 ]
Sundstrom, Stein H. [4 ]
von Plessen, Christian [5 ,6 ]
Brunsvig, Paal Fr. [7 ]
Bremnes, Roy M. [1 ,2 ]
机构
[1] Univ Hosp No Norway, Dept Oncol, N-9038 Tromso, Norway
[2] Univ Tromso, Inst Clin Med, N-9001 Tromso, Norway
[3] Univ Hosp No Norway, Dept Pulmonol, N-9038 Tromso, Norway
[4] St Olavs Univ hosp, Dept Oncol, Trondheim, Norway
[5] Haukeland Hosp, Dept Thorac Med, Bergen, Norway
[6] Univ Bergen, Inst Med, N-5020 Bergen, Norway
[7] Rikshosp HF, Dept Oncol, Oslo, Norway
关键词
Chemotherapy; NSCLC; Palliative; Poor performance status; Quality of life; Representative population;
D O I
10.1016/j.lungcan.2008.03.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: There is no consensus regarding chemotherapy to patients with advanced NSCLC (ANSCLC) and performance status (PS) 2. Using data from a national multicenter study comparing two third-generation carboplatin-based regimens in ANSCLC patients, we evaluated the outcome of PS 2 patients. Patients and methods: The 123 PS 2 patients were compared to 309 PS 0/1 patients regarding survival, quality of life (QOL) and treatment toxicity. Results: PS 2 patients had lower haemoglobin, lower global QOL and more pain, nausea/vomiting and dyspnea at inclusion. 68% of PS 2 patients received three chemotherapy courses vs. 85% in the PS 0/1 group (P < 0.01). Median and 1-year survival were lower in the PS 2 group, 4.5 vs. 8.9 months and 10% vs. 37% (P < .01). More PS 2 patients needed blood transfusions (P = 0.03) and hospitalization (P < 0.01). In contrast, PS 2 patients had better relief of pain and dyspnea, and tended to a better global QCL and did not experience more leucopoenia, infections or bleeding. Conclusions: Despite shorter survival, treatment toxicity was acceptable and PS 2 patients achieved better improvement of pain and dyspnea and tended to better global QOL when compared to PS 0/1 patients. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:253 / 260
页数:8
相关论文
共 34 条
[21]   Interpreting the significance of changes in health-related quality-of-life scores [J].
Osoba, D ;
Rodrigues, G ;
Myles, J ;
Zee, B ;
Pater, J .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :139-144
[22]   PROGNOSTIC FACTORS FOR SURVIVAL IN ADVANCED NON-SMALL-CELL LUNG-CANCER - UNIVARIATE AND MULTIVARIATE ANALYSES INCLUDING RECURSIVE PARTITIONING AND AMALGAMATION ALGORITHMS IN 1,052 PATIENTS [J].
PAESMANS, M ;
SCULIER, JP ;
LIBERT, P ;
BUREAU, G ;
DABOUIS, G ;
THIRIAUX, J ;
MICHEL, J ;
VANCUTSEM, O ;
SERGYSELS, R ;
MOMMEN, P ;
KLASTERSKY, J .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) :1221-1230
[23]   Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES) [J].
Perrone, F ;
Di Maio, M ;
Gallo, C ;
Gridelli, C .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (24) :5018-5020
[24]   American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003 [J].
Pfister, DG ;
Johnson, DH ;
Azzoli, CG ;
Sause, W ;
Smith, TJ ;
Baker, S ;
Olak, J ;
Stover, D ;
Strawn, JR ;
Turrisi, AT ;
Somerfield, MR .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) :330-353
[25]   A RANDOMIZED TRIAL OF THE 4 MOST ACTIVE REGIMENS FOR METASTATIC NON SMALL-CELL LUNG-CANCER [J].
RUCKDESCHEL, JC ;
FINKELSTEIN, DM ;
ETTINGER, DS ;
CREECH, RH ;
MASON, BA ;
JOSS, RA ;
VOGL, S .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (01) :14-22
[26]   Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J].
Schiller, JH ;
Harrington, D ;
Belani, CP ;
Langer, C ;
Sandler, A ;
Krook, J ;
Zhu, JM ;
Johnson, DH .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (02) :92-98
[27]   Chemotherapy improves low performance status lung cancer patients [J].
Sculier, J. P. ;
Lafitte, J. J. ;
Paesmans, M. ;
Lecmte, J. ;
Alexopoulos, C. G. ;
Van Cutsern, O. ;
Giner, V. ;
Efrernidis, A. ;
Berchier, M. C. ;
Colllon, T. ;
Meert, A. P. ;
Scherpereel, A. ;
Ninane, V. ;
Koumakis, G. ;
Vaslamatzis, M. M. ;
Leclercq, N. ;
Berghmans, T. .
EUROPEAN RESPIRATORY JOURNAL, 2007, 30 (06) :1186-1192
[28]   Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975 [J].
Smit, EF ;
van Meerbeeck, JPAM ;
Lianes, P ;
Debruyne, C ;
Legrand, C ;
Schramel, F ;
Smit, H ;
Gaafar, R ;
Biesma, B ;
Manegold, C ;
Neymark, N ;
Giaccone, G .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3909-3917
[29]   Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy? [J].
Soria, JC ;
Brisgand, D ;
Le Chevalier, T .
ANNALS OF ONCOLOGY, 2001, 12 (12) :1667-1670
[30]  
STANLEY KE, 1980, J NATL CANCER I, V65, P25